Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
Acrivon Therapeutics announced preclinical findings demonstrating strong synergistic effects of its lead cancer drug candidates ACR-368 and ACR-2316 when combined with anti-PD-L1 immune checkpoint inhibitors and antibody-drug conjugate (ADC) payloads, specifically Topoisomerase 1 inhibitors. These results support the potential for developing frontl…